Patents by Inventor Mirna MUJACIC

Mirna MUJACIC has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240159743
    Abstract: Provided herein are methods for assessing cell surface glycans, e.g., N-glycans, by assessing a sample of released surface glycans, and determining the presence, absence, or level of glycans present in the sample. Also provided are methods of assaying and/or evaluating a cell composition by assessing the cell surface glycan profile of the cell composition and comparing the profile to a reference sample. Methods for manufacturing and/or culturing a plurality of cell compositions having consistent surface glycan expression with low variability are also provided.
    Type: Application
    Filed: September 15, 2023
    Publication date: May 16, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Paul Ken KODAMA, Tom KOWSKI, Mirna MUJACIC, Kenneth Mayo PRENTICE
  • Publication number: 20240076617
    Abstract: Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods.
    Type: Application
    Filed: November 10, 2023
    Publication date: March 7, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Mirna MUJACIC, Ayu RAHARDJO
  • Publication number: 20230149462
    Abstract: Provided are methods and uses related to adoptive cell therapy involving the administration of doses of cells, such as T cells, for treating disease and conditions, including certain plasma cell malignancies. The cells express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM).
    Type: Application
    Filed: April 9, 2021
    Publication date: May 18, 2023
    Applicant: Juno Therapeutics, Inc.
    Inventors: Mariana Cota STIRNER, Mirna MUJACIC, Todd DEVRIES
  • Publication number: 20210395793
    Abstract: Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell-cycle inhibitors to growing cell cultures.
    Type: Application
    Filed: September 1, 2021
    Publication date: December 23, 2021
    Applicant: Amgen Inc.
    Inventors: Sandhya PANDE, Mirna MUJACIC
  • Publication number: 20210255173
    Abstract: Provided herein are methods for assessing cell surface glycans, e.g., N-glycans, by assessing a sample of released surface glycans, and determining the presence, absence, or level of glycans present in the sample. Also provided are methods of assaying and/or evaluating a cell composition by assessing the cell surface glycan profile of the cell composition and comparing the profile to a reference sample. Methods for manufacturing and/or culturing a plurality of cell compositions having consistent surface glycan expression with low variability are also provided.
    Type: Application
    Filed: April 13, 2018
    Publication date: August 19, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Paul Ken KODAMA, Tom KOWSKI, Mirna MUJACIC, Kenneth Mayo PRENTICE
  • Publication number: 20200384025
    Abstract: The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells and/or CD8+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for pooling enriched CD4+ and CD8+ cells, such as at a 1:1 ratio, and then incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.
    Type: Application
    Filed: December 7, 2018
    Publication date: December 10, 2020
    Applicant: Juno Therapeutics, Inc.
    Inventors: Mirna MUJACIC, Ayu RAHARDJO, Pascal BEAUCHESNE, Kien KHUU-DUONG, Ivie AIFUWA, Calvin CHAN
  • Publication number: 20200181575
    Abstract: Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naive-like CD4+ T cells to naive-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods.
    Type: Application
    Filed: August 9, 2018
    Publication date: June 11, 2020
    Applicant: Juno Therapeutics, Inc.
    Inventors: Mirna MUJACIC, Ayu RAHARDJO
  • Publication number: 20160281124
    Abstract: Methods of modulating high mannose glycoform content of a protein in a cell culture by contacting the cells expressing the protein of interest with monesin are provided.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 29, 2016
    Applicant: AMGEN INC.
    Inventors: Sandhya PANDE, Mirna MUJACIC
  • Publication number: 20150376221
    Abstract: Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein.
    Type: Application
    Filed: February 20, 2014
    Publication date: December 31, 2015
    Inventors: John Gordon Allen, Christopher H. FOTSCH, Michael J. FROHN, John Douglas MCCARTER, Mirna MUJACIC, Alexander J. PICKRELL